Polymorphisms of a novel long non-coding RNA RP11-108K3.2 with colorectal cancer susceptibility and their effects on its expression

Abstract

Background:

RP11-108K3.2 was recently identified as a novel long non-coding RNA (lncRNA) transcript, and several single nucleotide polymorphisms (SNPs) have been identified in its coding region. This study aimed to explore the associations of tagSNPs in RP11-108K3.2 with the risk of colorectal cancer and their effects on its expression.

Methods:

A total of 821 colorectal cancer cases and 857 healthy controls were enrolled into this two-stage case-control study. Demographic characteristics and lifestyle information were collected by a validated questionnaire. Six tagSNPs were genotyped by using Sequenom MassARRAY platform. A total of 71 additional colorectal cancer cases were recruited, of which the genotypes of potential polymorphisms and the RP11-108K3.2 expression levels were determined.

Results:

In the discovery set, only the rs2470151 C/T polymorphism was found to have a promising association with the risk of colorectal cancer, and this polymorphism was further replicated in the validation set with a significantly decreased risk of colorectal cancer (adjusted odds ratio 0.73; 95% confidence interval 0.55, 0.97). Combined discovery set and validation set together, this negative association was found both in the heterozygote codominant model and the dominant model. Furthermore, colorectal cancer patients carrying rs2470151 CT/TT genotypes had a marginally lower RNA expression of RP11-108K3.2 than those carrying the CC genotype. Stratified analyses showed the association between rs2470151 and the risk of colorectal cancer were influenced by family history of cancer, smoking, alcohol consumption, and tea drinking.

Conclusions:

These findings suggest that RP11-108K3.2 rs2470151 had a significant association with the risk of colorectal cancer; this may help to predict the susceptibility of colorectal cancer in Chinese populations.

Keywords

Long non-coding RNA single nucleotide polymorphism rs2470151 colorectal cancer

Introduction

Colorectal cancer (CRC) is the third most common cancer and ranks fourth in cancer deaths globally, accounting for roughly 1.2 million new cases and 600,000 deaths every year.¹ Since CRC is a significant threat to public health, a substantial number of studies have investigated its etiology. Apart from age and sex, the following factors have been identified and established to be associated with the risk of CRC in epidemiological studies: family history of CRC, inflammatory bowel disease, smoking, excessive alcohol consumption, high consumption of red and processed meat, obesity, and diabetes.

A substantial number of genetic components play important roles in CRC susceptibility. Elevated genome-wide association studies have indicated that single nucleotide polymorphisms (SNPs) were involved.^2-4 Among the numerous SNPs demonstrated to be related to CRC, variants located on the coding region of long non-coding RNAs (lncRNAs) have drawn attention. For example, a two-stage case-control study suggests that genetic variants of HOTAIR rs7958904 may act as a potential biomarker for predicting the risk of CRC.⁵

lncRNAs are a large category of transcripts without protein-coding potential, which are >200 nt in length. Although the definite biological roles of most lncRNAs are still unknown, a growing number of literature suggests that they have a wide variety of roles in chromatin remodeling, transcriptional activation, transcriptional repressor, and RNA degradation.^6-8 The genetic polymorphisms on lncRNA coding regions may have implications for many human diseases, including cancer, by changing their expression levels.⁹

RP11-108K3.2 was recently identified as a novel lncRNA, and its coding region maps on the 15q21 chromosome, which is overlapped by the cytochrome P450 family 19 subfamily A member 1 (CYP19A1) gene. CYP19A1 influences estrogen-metabolizing enzymes and may change the CRC risk through an inflammation-related mechanism. A previous population-based, case-control study suggests that several polymorphisms in the CYP19A1 gene are associated with the risk of CRC,¹⁰ which may have a stronger effect in women due to the influences of sex hormone.¹¹

In this study, we hypothesized that tagSNPs located on RP11-108K3.2 may be involved in the susceptibility to CRC. To test this hypothesis, we conducted a two-stage, case-control study to explore the association between the tagSNPs of RP11-108K3.2 and the risk of CRC in a Chinese population. We further analyzed the expression levels of RP11-108K3.2 among different genotype carriers if the polymorphism has been proven to be associated with the risk of CRC.

Materials and methods

Study subjects

This study was performed in Jiashan County, Zhejiang Province, China, based on a population screening program. All CRC cases were histopathologically confirmed by the Jiashan Institute of Cancer Prevention and Treatment since 1989. Healthy controls were recruited in parallel from the same population and matched to the cases by age (± 5 years), gender, and residential area. Subjects were excluded if they self-reported a history of familial adenomatous polyposis, ulcerative colitis, or Crohn disease. The recruitment details of the study population have been described previously.¹² Briefly, this two-stage, case-control study ultimately enrolled 320 CRC cases and 319 healthy controls in the discovery set; and 501 CRC cases and 538 healthy controls in the validation set. A face-to-face interview was conducted by trained interviewers using a structured questionnaire to collect the information of demographic characteristics (e.g. age, gender, and body mass index (BMI)), family history of cancer and lifestyle factors (e.g. smoking, alcohol consumption, and tea drinking). The definition of a family history of cancer was a first- or second-degree relative having had cancer at any site. Smokers were defined as those who smoked at least one cigarette per day for more than 1 year, or >300 cigarettes in less than 3 months. Alcohol drinkers were defined as those who consumed at least one alcohol drink per day for more than 3 months. Tea drinkers were defined as those who consumed more than two times of tea drink per week for more than 2 months. Blood sample of each participant was collected and stored at −80°C for DNA isolation.

This study also recruited 71 CRC tissues from patients who underwent surgical operations at the Department of Gastrointestinal Surgery, Hangzhou First People’s Hospital from July 2013 to December 2013. The tissues were preserved in the RNA Later^® Stabilization Solution (Invitrogen, Carlsbad, CA, USA) and stored at −80°C.

The written informed consent was obtained from all subjects and this study was approved by the Medical Ethical Committee of Zhejiang University School of Medicine.

SNP selection and genotyping

We selected the tagSNPs that were located on the 2000bp upstream region of RP11-108K3.2 with pairwise correlation r²>0.80 and minor allele frequencies (MAF) > 0.10. Genomic DNA was extracted from peripheral blood by using the modified salting-out procedure. Genotyping was performed by the MassARRAY molecular weight array analysis system (BioMiao Biological Technology Co., Beijing, China). A negative control was included in each 96-well plate for quality control. The 5% of samples were randomly selected for repeated detection and the concordance rate was >99%. Primer information of SNPs of RP11-108K3.2 is shown in Supplementary Table 1.

RNA isolation and quantitative RT-PCR

Total RNA was isolated using a homogenizer (IKA^® Works Guangzhou, China) and TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and then purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. A reverse transcription real-time PCR (RT-PCR) was conducted with StepOnePlus instrument (Applied Biosystems, Foster City, CA, USA) to synthesize cDNA. We performed quantitative real-time PCR in StepOnePlus System (Applied Biosystems, Foster City, CA, USA) using SYBR Green Master Mix (Vazyme, Nanjing, China) to quantify relative RP11-108K3.2 expression levels. The specific forward primer and reverse primer were 5′-GCTGGAACCCAATGGATGA-3′ and 5′-CCTGGAGAATGTAGCAATGGAA-3′. The β-actin was selected as the endogenous control. The specific forward primer and reverse primer were 5′-GTGGCCGAGGACTTTGATTG-3′ and 5′-CCTGTAACAACGCATCTCATATT-3′. All procedures were carried out in triplicate. For quantitative results, the expression of RP11-108K3.2 was calculated according to fold change using the 2^−ΔCt method.

Statistical analysis

The Student’s t-test and Pearson’s χ2 test were applied to evaluate the differences of characteristics between cases and controls. Hardy–Weinberg equilibrium was assessed by goodness-of-fitχ2 test. The association between tagSNPs and the risk of CRC was estimated by calculating the adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) in multivariate logistic regression model. Those tagSNPs with a P-value less than 0.20 in the association study of discovery set were further analyzed in the validation set. Pooled analyses were also conducted to estimate the combined effect of these two sets. Different expression levels of lncRNA in samples of different genotypes were analyzed using ANOVA analysis or t-test.

All analyses were performed with SAS software (version 9.2; SAS Institute, Inc., Cary, NC, USA) with two-sided P-values. P < 0.05 was considered statistically significant.

Results

Characteristics of the study population

In the discovery set, the mean age was 65.8 years (range, 35–87 years) for the cases, and 65.3 years (range, 34–89 years) for the controls. In the validation set, the mean age was 62.7 years (range, 32–95 years) for the cases, and 62.3 years (range, 33–92 years) for the controls (Supplementary Table 2). CRC patients had a higher percentage of a family history of cancer (P < 0.001 in the discovery set, P = 0.039 in the validation set) and a lower proportion of tea drinking (P = 0.030 in the validation set) than controls. There was no significant difference in other demographic characteristics (age, gender, BMI) or lifestyle factors (smoking, alcohol drinking) between cases and controls.

Association between RP11-108K3.2 tagSNPs and the risk of colorectal cancer

As shown in Table 1, six tagSNPs were included in the discovery set (rs2470151, rs3751591, rs3751592, rs77348531, rs17602308, and rs75106900), all of which conformed to the request of Hardy–Weinberg equilibrium. However, only the CT genotype of rs2470151 found a promising association after adjusting for age, gender, BMI, family history of cancer, smoking, alcohol consumption, and tea drinking (adjusted OR 0.74; 95% CI 0.51, 1.07; P = 0.106). The other tagSNPs were observed to have no meaningful association with the risk of CRC (P > 0.20).

Table 1.

The association between tagSNPs of RP11-108K3.2 and the risk of colorectal cancer in the discovery set.

Genotype	Cases, N (%)	Controls, N (%)	Crude		Adjusted^a
Genotype	Cases, N (%)	Controls, N (%)	OR (95% CI)	P-value	OR (95% CI)^a	P-value^b
rs2470151
CC	121 (37.93)	103 (32.59)	1		1
CT	143 (44.83)	155 (49.05)	0.88 (0.74, 1.06)	0.173	0.74 (0.51, 1.07)	0.106
TT	55 (17.24)	58 (18.35)	0.90 (0.71, 1.13)	0.354	0.80 (0.50, 1.29)	0.367
rs3751591
AA	243 (76.66)	231 (73.33)	1		1
AG	67 (21.14)	75 (23.81)	0.92 (0.77, 1.11)	0.393	0.83 (0.56, 1.23)	0.348
GG	7 (2.21)	9 (2.86)	0.87 (0.56, 1.35)	0.554	0.66 (0.23, 1.87)	0.430
rs3751592
TT	239 (74.69)	239 (75.39)	1		1
TC	74 (23.13)	74 (23.34)	1.00 (0.83, 1.20)	1.000	0.95 (0.65, 1.40)	0.797
CC	7 (2.19)	4 (1.26)	1.38 (0.63, 3.02)	0.371	1.76 (0.49, 6.30)	0.383
rs77348531
AA	192 (60.00)	182 (57.05)	1		1
AG	106 (33.13)	115 (36.05)	0.94 (0.79, 1.10)	0.427	0.91 (0.64, 1.29)	0.581
GG	22 (6.88)	22 (6.90)	0.97 (0.71, 1.33)	0.867	1.14 (0.59, 2.19)	0.700
rs17602308
TT	262 (82.13)	261 (82.86)	1		1
TC	53 (16.61)	52 (16.51)	1.01 (0.82, 1.25)	0.943	1.04 (0.67, 1.62)	0.846
CC	4 (1.25)	2 (0.63)	1.50 (0.48, 4.66)	0.420	2.24 (0.40, 12.48)	0.359
rs75106900
C/C	189 (59.25)	178 (56.51)	1		1
C/DEL	106 (33.23)	114 (36.19)	0.94 (0.79, 1.10)	0.437	0.89 (0.63, 1.26)	0.518
DEL/DEL	24 (7.52)	23 (7.30)	0.99 (0.73, 1.35)	0.955	1.19 (0.63, 2.24)	0.598

BMI: body mass index; CI: confidence interval; OR: odds ratio.

Adjusted for age, gender, BMI, occupation, education level, marital status, family history of cancer, smoking, alcohol consumption, and tea drinking.

The tagSNPs with a P-value less than 0.20 in the discovery set were further analyzed in the validation set.

P < 0.20 is in bold, P-value < 0.20 is further analyzed in the validation set.

The validation set carried on with the RP11-108K3.2 rs2470151 polymorphism, which was observed to be significantly associated with the risk of CRC in the validation set and the combined set (Table 2). In the validation set, subjects with the CT genotype had a significantly decreased risk of CRC compared with subjects with the CC genotype by a co-dominant model (adjusted OR 0.73; 95% CI 0.55, 0.97; P = 0.030), and this association was confirmed in the combined set (adjusted OR 0.73; 95% CI 0.58, 0.92; P = 0.007). However, the rs2470151 TT genotype did not show a significant difference, which may be due to the low genotype frequency. Also, we applied the dominant model to evaluate the effect of rs2470151 on the CRC risk; it still indicated the CT/TT genotype as being a protective factor for CRC in the combined set (adjusted OR 0.79; 95% CI 0.64, 0.97; P = 0.025). A subgroup analysis by gender is shown in Supplementary Table 3, which indicates that the association was stronger in females than males.

Table 2.

Significant association between RP11-108K3.2 rs2470151 and the risk of colorectal cancer.

Genotype	Cases, N (%)	Controls, N (%)	Crude		Adjusted^a
Genotype	Cases, N (%)	Controls, N (%)	OR (95% CI)	P-value	OR (95% CI)^a	P-value^b
Discovery set
CC	121 (37.93)	103 (32.59)	1		1
CT	143 (44.83)	155 (49.05)	0.79 (0.56, 1.11)	0.173	0.74 (0.51, 1.07)	0.106
TT	55 (17.24)	58 (18.35)	0.81 (0.51, 1.27)	0.354	0.80 (0.50, 1.29)	0.367
CT+TT	198 (62.07)	213 (67.41)	0.79 (0.57, 1.10)	0.159	0.75 (0.53, 1.06)	0.107
Validation set
CC	176 (35.48)	159 (29.94)	1		1
CT	229 (46.17)	290 (54.61)	0.71 (0.54, 0.94)	0.016	0.73 (0.55, 0.97)	0.030
TT	91 (18.35)	82 (15.44)	1.00 (0.69, 1.45)	0.989	1.03 (0.71, 1.51)	0.872
CT+TT	320 (64.52)	372 (70.06)	0.78 (0.60, 1.01)	0.058	0.80 (0.61, 1.05)	0.103
Combined set
CC	297 (36.44)	262 (30.93)	1		1
CT	372 (45.64)	445 (52.54)	0.74 (0.59, 0.92)	0.006	0.73 (0.58, 0.92)	0.007
TT	146 (17.91)	140 (16.53)	0.92 (0.69, 1.22)	0.566	0.94 (0.70, 1.26)	0.659
CT+TT	518 (63.56)	585 (69.07)	0.78 (0.64, 0.96)	0.017	0.79 (0.64, 0.97)	0.025

BMI: body mass index; CI: confidence interval; OR: odds ratio.

Adjusted for age, gender, BMI, occupation, education level, marital status, family history of cancer, smoking, alcohol consumption, and tea drinking.

P < 0.20 was applied as the criteria to screen genotypes in the discovery set, and P < 0.05 was used as the criteria to testify rs2470151 genotype in the validation set.

P < 0.05 is in bold, P < 0.05 is considered as statistically significant.

Correlation between rs2470151 genotypes and RP11-108K3.2 expression

Of the 71 CRC tissue samples, CC genotypes were identified in 18 cases (25.4%), CT genotypes in 40 cases (56.3%), and TT genotypes in 13 cases (18.3%). As shown in Figure 1, the relative expression level of RP11-108K3.2 was marginally higher in individuals carrying CC genotypes than in those carrying CT/TT genotypes (fold change = 1.765). The association between RP11-108K3.2 expression levels and clinic pathological characteristics was not statistically significant (Supplementary Table 4).

Figure 1.

Relative expression level of RP11-108K3.2 mRNA grouped by rs2470151 genotypes in 71 colorectal cancer tissues.

Stratified analysis by selected variables between rs2470151 variant and the risk of CRC

Stratified analyses by selected variables were conducted for the RP11-108K3.2 rs2470151 variant (Table 3). In the subjects without a family history of cancer, CT/TT carriers of rs2470151 had a lower risk of CRC compared with CC carriers (adjusted OR 0.77; 95% CI 0.62, 0.98; P = 0.029). In the combined set, smokers with the CT/TT genotypes had a lower risk of CRC than those with the CC genotype (adjusted OR 0.64; 95% CI 0.45, 0.92; P = 0.014). Non-drinkers with the CT/TT genotypes had a significantly decreased risk of CRC compared with those with the CC genotype (adjusted OR 0.77; 95% CI 0.61, 0.99; P = 0.039). In the non-tea drinkers, carrying the CT/TT genotypes seemed to be a protective factor for CRC (adjusted OR 0.70; 95% CI 0.53, 0.92; P = 0.011).

Table 3.

Risk of colorectal cancer associated with rs2470151 stratified by family history of cancer, smoking, alcohol consumption, and tea drinking.

Variables	Genotype	Discovery set			Validation set			Combined set
Variables	Genotype	N_cases/N_controls	Adjusted OR (95% CI)^a	P-value	N_cases/N_controls	Adjusted OR (95% CI)^a	P-value	N_cases/N_controls	Adjusted OR (95% CI)^a	P-value
Family history of cancer
No	CC*	101/96	1		135/128	1		236/224	1
	CT+TT	155/189	0.76 (0.53, 1.09)	0.141	255/316	0.80 (0.59, 1.08)	0.138	410/505	0.77 (0.62, 0.98)	0.029
Yes	CC*	20/6	1		41/31	1		61/37	1
	CT+TT	43/23	0.65 (0.21, 1.96)	0.441	65/56	0.75 (0.40, 1.41)	0.378	108/79	0.80 (0.47, 1.34)	0.389
Smoking
No	CC*	74/76	1		105/94	1		179/170	1
	CT+TT	133/141	0.91 (0.60, 1.38)	0.666	208/230	0.85 (0.60, 1.20)	0.365	341/371	0.88 (0.67, 1.14)	0.324
Yes	CC*	47/27	1		71/65	1		118/92	1
	CT+TT	65/72	0.50 (0.27, 0.93)	0.029	110/140	0.71 (0.46, 1.10)	0.127	175/212	0.64 (0.45, 0.92)	0.014
Alcohol drinking
No	CC*	94/86	1		126/108	1		220/194	1
	CT+TT	152/159	0.84 (0.57, 1.22)	0.355	231/273	0.74 (0.54, 1.01)	0.060	383/432	0.77 (0.61, 0.99)	0.039
Yes	CC*	26/15	1		47/48	1		73/63	1
	CT+TT	46/53	0.41 (0.17, 0.95)	0.038	88/95	0.96 (0.57, 1.62)	0.880	134/148	0.78 (0.51, 1.20)	0.259
Tea drinking
No	CC*	75/65	1		107/71	1		182/136	1
	CT+TT	124/125	0.82 (0.53, 1.26)	0.355	185/201	0.62 (0.43, 0.90)	0.011	309/326	0.70 (0.53, 0.92)	0.011
Yes	CC*	46/38	1		68/88	1		114/126	1
	CT+TT	74/88	0.63 (0.36, 1.11)	0.113	130/165	1.13 (0.75, 1.69)	0.569	204/253	0.92 (0.67, 1.28)	0.629

BMI: body mass index; CI: confidence interval; OR: odds ratio.

reference group.

Adjusted for age, gender, BMI, occupation, education level, marital status, family history of cancer, smoking, alcohol consumption, and tea drinking.

P < 0.05 is in bold, P < 0.05 is considered as statistically significant.

Discussion

CRC is a major cause of morbidity and mortality worldwide.¹³ One of the fundamental processes driving the initiation and progression of CRC is the accumulation of a variety of genetic and epigenetic changes in the colorectum.⁸ Here, we explored the associations between the tagSNPs on RP11-108K3.2 and the risk of CRC, and identified rs2470151 as a potential biomarker for CRC through a two-stage, case-control study. This association between rs2470151 and the risk of CRC was influenced by selected variables including a family history of cancer, smoking, alcohol consumption, and tea drinking. Moreover, carrying the CC genotype of rs2470151 may increase RP11-108K3.2 expression levels compared to the CT/TT carriers. To the best of our knowledge, this is the first study to explore the effect of RP11-108K3.2 on the risk of CRC.

lncRNAs are implicated in serial steps of cancer development, interacting with DNA, RNA, protein molecules, and/or their combinations, acting as an essential regulator in chromatin organization, and in transcriptional and post-transcriptional regulation.¹⁴ There is increasing evidence revealing that SNPs on lncRNAs may be correlated with cancer, which may influence the expression of RNA or the stability of RNA conformation, resulting in the modification of its interacting partners. SNP variants on lncRNAs were observed to function in different cancer types, including gastric cancer,^15,16 lung cancer,^17,18 prostate cancer,^19,20 and breast cancer.^21,22 Several studies also have reported that SNPs on lncRNAs are related to the risk of CRC. For example, Ling et al.²³ reported that a novel lncRNA CCAT2 was highly overexpressed in microsatellite-stable CRC, and the SNP status affected its expression, and the risk allele G of rs6983267 produced more CCAT2 transcript. Li et al.²⁴ demonstrated that rs13252298 and rs1456315 on the lncRNAPRNCR1 were significantly associated with the decreased risk of CRC. Haiman et al.²⁵ revealed that rs6983267 mapping on the 8q24 chromosomal region was also related to the risk of CRC. Based on the results of current studies, we hypothesized that the SNP rs2470151 may influence the expression of RP11-108K3.2, resulting in its subsequent biological processes. In our study, we observed that the CT/TT genotype carriers of rs2470151 polymorphism (C>T) had a significantly decreased risk of CRC compared with the subjects with CC genotype. Furthermore, different genotype carriers had different expression levels of RP11-108K3.2 in CRC tissues; however, the difference was not significant.

In previous epidemiological studies, there was quite a lot of evidence supporting the association between polymorphisms and different lifestyle factors, including smoking, alcohol, body fatness, diet, physical activity, and medications, in CRC.^26-29 Bailie et al.³⁰ also described several lifestyle factors associated with higher colorectal disease risk, most notably smoking and alcohol. Besides the factors above, family history is a well-established risk factor for CRC.³¹ In our study, we also demonstrated that the association between the risk of CRC and RP11-108K3.2 rs2470151 may be influenced by selected variables, including a family history of cancer, alcohol consumption, and tea drinking through stratified analyses.

There are several limitations in this study. First, although we observed a significant association between rs2470151 and the risk of CRC, how the genetic variability at this locus influences RP11-108K3.2 to function still remains to be fully elucidated. Second, the recall bias of lifestyle factors was inevitable in a case-control study. Third, most of the clinical information of the CRC cases was absent due to the population-based study. Fourth, the associations might have insufficient statistical power due to the relatively moderate sample size, and further studies with larger samples are expected to confirm our findings, especially in the subgroup analysis and correlation study between rs2470151 genotypes and RP11-108K3.2 expression levels.

In summary, we have provided initial evidence that subjects carrying the rs2470151 CT/TT genotype had significantly lower CRC risk than those with the CC genotype. We also indicated that the CT/TT genotype of rs2470151 may have an effect on the lower expression level for RP11-108K3.2. This association between rs2470151 polymorphism and the risk of CRC may be influenced by a family history of cancer, alcohol consumption, and tea drinking. These results suggest that the SNP rs2470151 on RP11-108K3.2 may help to predict the CRC risk in Chinese populations.

Supplemental Material

Supplementary_Table_1 – Supplemental material for Polymorphisms of a novel long non-coding RNA RP11-108K3.2 with colorectal cancer susceptibility and their effects on its expression

Supplemental material, Supplementary_Table_1 for Polymorphisms of a novel long non-coding RNA RP11-108K3.2 with colorectal cancer susceptibility and their effects on its expression by Danjie Jiang, Mingjuan Jin, Ding Ye, Yingjun Li, Fangyuan Jing, Xiaocong Zhang, Qilong Li and Kun Chen in The International Journal of Biological Markers

Footnotes

Author contributions

Danjie Jiang and Mingjuan Jin contributed equally to this work.

Declaration of conflicting interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Natural Science Foundation of China (No.81673262 and 81373087), the National Key Basic Research Program (973 program No.2015CB554003), the Natural Science Foundation of Zhejiang Province, China (No.LQ15H260001), and the Zhejiang Chinese Medical University Foundation (No.2019ZR03).

ORCID iD

Danjie Jiang

Supplemental material

Supplemental material for this article is available online.

References

Brenner

Kloor

Pox

CP.

Colorectal cancer. Lancet 2014; 383: 1490–1502.

Al-Tassan

Whiffin

Hosking

, et al. A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Sci Rep 2015; 5: 10442.

Peters

Jiao

Schumacher

, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 2013; 144: 799–807.

Theodoratou

Montazeri

Hawken

, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 2012; 104: 1433–1457.

Xue

, et al. Genetic variants in lncRNA HOTAIR are associated with risk of colorectal cancer. Mutagenesis 2015; 30: 303–310.

Derrien

Johnson

Bussotti

, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012; 22: 1775–1789.

Guttman

Rinn

JL.

Modular regulatory principles of large non-coding RNAs. Nature 2012; 482: 339–346.

Okugawa

Grady

Goel

Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 2015; 149: 1204–1225.

Zhang

Zhou

, et al. The identification of an ESCC susceptibility SNP rs920778 that regulates the expression of lncRNA HOTAIR via a novel intronic enhancer. Carcinogenesis 2014; 35: 2062–2067.

10.

Slattery

Lundgreen

Herrick

, et al. Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control 2011; 22: 955–963.

11.

Lin

Manson

Kraft

, et al. Estrogen and progesterone-related gene variants and colorectal cancer risk in women. BMC Med Genet 2011; 12: 78.

12.

Zhang

Liu

Jin

, et al. Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based case-control study in China. Cancer Lett 2009; 275: 102–108.

13.

Dickinson

Kisiel

Ahlquist

, et al. Molecular markers for colorectal cancer screening. Gut 2015; 64: 1485–1494.

14.

Han

Wang

, et al. Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett 2015; 361: 13–21.

15.

Wang

Jin

, et al. The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population. Oncotarget 2015; 6: 31255–31262.

16.

Pan

Liu

Wei

, et al. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility. Mol Carcinog 2016; 55: 90–96.

17.

Chen

, et al. Clinical significance of long non-coding RNA CASC8 rs10505477 polymorphism in lung cancer susceptibility, platinum-based chemotherapy response, and toxicity. Int J Environ Res Public Health 2016; 13.

18.

Yuan

Liu

, et al. A novel genetic variant in long non-coding RNA gene NEXN-AS1 is associated with risk of lung cancer. Sci Rep 2016; 6: 34234.

19.

Guo

Ahmed

Zhang

, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet 2016; 48: 1142–1150.

20.

Jin

Sun

Isaacs

, et al. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis 2011; 32: 1655–1659.

21.

Ingle

Xie

Ellis

, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Res 2016; 76: 7012–7023.

22.

Yan

Cao

Song

, et al. Polymorphisms in lncRNA HOTAIR and susceptibility to breast cancer in a Chinese population. Cancer Epidemiol 2015; 39: 978–985.

23.

Ling

Spizzo

Atlasi

, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013; 23: 1446–1461.

24.

Sun

Liang

, et al. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J Exp Clin Cancer Res 2013; 32: 104.

25.

Haiman

Le Marchand

Yamamato

, et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet 2007; 39: 954–956.

26.

Andersen

Egeberg

Tjonneland

, et al. Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study. BMC Cancer 2012; 12: 183.

27.

Andersen

Holst

Kopp

, et al. Interactions between diet, lifestyle and IL10, IL1B, and PTGS2/COX-2 gene polymorphisms in relation to risk of colorectal cancer in a prospective Danish case-cohort study. PLoS One 2013; 8: e78366.

28.

Kopp

Andersen

Tjonneland

, et al. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. Scand J Gastroenterol 2015; 50: 1469–1481.

29.

Kopp

Andersen

Tjonneland

, et al. Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. PLoS One 2015; 10: e0116394.

30.

Bailie

Loughrey

Coleman

HG.

Lifestyle Risk Factors for Serrated Colorectal Polyps: A Systematic Review and Meta-analysis. Gastroenterology 2017; 152: 92–104.

31.

Fuchs

Giovannucci

Colditz

, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331: 1669–1674.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB